The effects of deucravacitinib on three cases of systemic sclerosis associated with psoriasis

Rheumatology (Oxford). 2025 Jan 9:keaf019. doi: 10.1093/rheumatology/keaf019. Online ahead of print.

Authors

Takemichi Fukasawa^{1

2}, Asako Yoshizaki-Ogawa¹, Ayumi Yoshizaki^{1

2

3}, Shinichi Sato^{1

3}

Affiliations

¹ Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
² Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
³ Systemic sclerosis center, The University of Tokyo Hospital, Tokyo, Japan.

PMID: 39786840
DOI: 10.1093/rheumatology/keaf019

No abstract available

Keywords: deucravacitinib; fibrosis; immune abnormalities; psoriasis; systemic sclerosis; vasculopathy.